Atriance launched for lymph cancer

GSK has launched Atriance (nelarabine) for the treatment of patients with T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded, or has relapsed, following treatment with at least two chemotherapy regimens.

Further information: GSK 0800 221441

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Additional tiotropium inhaler available to prescribe

Additional tiotropium inhaler available to prescribe

Acopair is delivered by the dry powder NeumoHaler device.

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

New and deleted indications - live tracker

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...